Hypoglycemics, Lantus Insulin
|
|
|
- Darleen Goodman
- 5 years ago
- Views:
Transcription
1 Texas Prior Authorization Program PDL Edit Criteria Drug/Drug Class Hypoglycemics, Lantus Insulin Information Included in this Document Hypoglycemics, Lantus Insulin Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical edit Prior authorization criteria logic: a description of how the prior authorization request will be evaluated against the clinical edit criteria rules Logic diagram: a visual depiction of the clinical edit criteria logic Supporting tables: a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes); provided when applicable References: clinical publications and sources relevant to this clinical edit Note: Click the hyperlink to navigate directly to that section. Revision Notes Lantus insulin moved from non-preferred status to preferred status. Edit removed. 03/26/2015 Copyright Health Information Designs, LLC 1
2 Drugs Requiring Prior Authorization Lantus Insulin Label Name GCN LANTUS 100 UNITS/ML VIAL LANTUS SOLOSTAR 100 UNITS/ML /26/2015 Copyright Health Information Designs, LLC 2
3 PDL Edit Criteria Logic 1. Is the client less than (<) 18 years of age? [ ] Yes (Go to #2) [ ] No (Go to #3) 2. Does the client have a diagnosis of type I diabetes in the last 730 days? [ ] Yes (Approve 365 days) [ ] No (Go to #3) 3. Has the client failed a 30-day treatment trial with at least 1 preferred agent within the past 180 days? [ ] Yes (Approve 365 days) [ ] No (Go to #4) 4. Is there a documented allergy or contraindication to preferred agents in this class? [ ] Yes (Approve 365 days) [ ] No (Deny) 03/26/2015 Copyright Health Information Designs, LLC 3
4 PDL Edit Criteria Logic Diagram Step 1 Step 2 Is the client less than 18 years of age? Yes Does the client have a diagnosis of type I diabetes in the last 730 days? Yes Approve Request (365 days) No No Step 3 Has the client failed a 30-day treatment trial with at least 1 preferred agent within the past 180 days? Yes Approve Request (365 days) No Step 4 Is there a documented allergy or contraindication to preferred agents in this class? Yes Approve Request (365 days) No Deny Request 03/26/2015 Copyright Health Information Designs, LLC 4
5 PDL Edit Criteria Supporting Tables ICD-9 Code Description Step 2 (diagnosis of type I diabetes) Required quantity: 1 Look back timeframe: 730 days DIABETES MELLITUS W/O MENTION OF COMPLICATION, TYPE 1 [JUVENILE TYPE], NOT STATED AS UNCONTROLLED DIABETES MELLITUS W/O MENTION OF COMPLICATION, TYPE 1 [JUVENILE TYPE], UNCONTROLLED DIABETES WITH KETOACIDOSIS, TYPE I [JUVENILE TYPE], NOT STATED AS UNCONTROLLED DIABETES WITH KETOACIDOSIS, TYPE I [JUVENILE TYPE], UNCONTROLLED DIABETES WITH HYPEROSMOLARITY, TYPE 1 [JUVENILE TYPE], NOT STATED AS UNCONTROLLED DIABETES WITH HYPEROSMOLARITY, TYPE 1 [JUVENILE TYPE], UNCONTROLLED DIABETES WITH OTHER COMA, TYPE 1 [JUVENILE TYPE], NOT STATED AS UNCONTROLLED DIABETES WITH OTHER COMA, TYPE 1 [JUVENILE TYPE], UNCONTROLLED DIABETES WITH RENAL MANIFESTATIONS, TYPE 1 [JUVENILE TYPE], NOT STATED AS UNCONTROLLED DIABETES WITH RENAL MANIFESTATIONS, TYPE 1 [JUVENILE TYPE], UNCONTROLLED DIABETES WITH OPHTHALMIC MANIFESTATIONS, TYPE 1 [JUVENILE TYPE], NOT STATED AS UNCONTROLLED DIABETES WITH OPHTHALMIC MANIFESTATIONS, TYPE 1 [JUVENILE TYPE], UNCONTROLLED DIABETES WITH NEUROLOGICAL MANIFESTATIONS, TYPE 1 [JUVENILE TYPE], NOT STATED AS UNCONTROLLED DIABETES WITH NEUROLOGICAL MANIFESTATIONS, TYPE 1 [JUVENILE TYPE], UNCONTROLLED DIABETES WITH PERIPHERAL CIRCULATORY DISORDERS, TYPE 1 [JUVENILE TYPE], NOT STATED AS UNCONTROLLED DIABETES WITH PERIIPHERAL CIRCULATORY DISORDERS, TYPE 1 [JUVENILE TYPE], UNCONTROLLED DIABETES WITH OTHER SPECIFIED MANIFESTATIONS, TYPE 1 [JUVENILE TYPE], NOT STATED AS UNCONTROLLED DIABETES WITH OTHER SPECIFIED MANIFESTATIONS, TYPE 1 [JUVENILE TYPE], UNCONTROLLED DIABETES WITH UNSPECIFIED COMPLICATION, TYPE 1 [JUVENILE TYPE], NOT STATED AS UNCONTROLLED 03/26/2015 Copyright Health Information Designs, LLC 5
6 ICD-9 Code Description Step 2 (diagnosis of type I diabetes) Required quantity: 1 Look back timeframe: 730 days DIABETES WITH UNSPECIFIED COMPLICATION, TYPE 1 [JUVENILE TYPE], UNCONTROLLED ICD-10 Code E10 Description TYPE 1 DIABETES MELLITUS E10.1 TYPE 1 DIABETES MELLITUS WITH KETOACIDOSIS E10.10 TYPE 1 DIABETES MELLITUS WITH KETOACIDOSIS, WITHOUT COMA E10.11 TYPE 1 DIABETES MELLITUS WITH KETOACIDOSIS, WITH COMA E10.2 TYPE 1 DIABETES MELLITUS WITH KIDNEY COMPLICATIONS E10.21 TYPE 1 DIABETES MELLITUS WITH DIABETIC NEPHROPATHY E10.22 TYPE 1 DIABETES MELLITUS WITH DIABETIC CHRONIC KIDNEY DISEASE E10.29 TYPE 1 DIABETES MELLITUS WITH OTHER DIABETIC KIDNEY COMPLICATION E10.3 TYPE 1 DIABETES MELLITUS WITH OPHTHALMIC COMPLICATIONS E10.31 TYPE 1 DIABETES MELLITUS WITH UNSPECIFIED DIABETIC RETINOPATHY E TYPE 1 DIABETES MELLITUS WITH UNSPECIFIED DIABETIC RETINOPATHY WITH MACULAR EDEMA E TYPE 1 DIABETES MELLITUS WITH UNSPECIFIED DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA E10.32 TYPE 1 DIABETES MELLITUS WITH MILD NONPROLIFERATIVE DIABETIC RETINOPATHY E TYPE 1 DIABETES MELLITUS WITH MILD NONPROLIFERATIVE DIABETIC RETINOPATHY WITH MACULAR EDEMA E TYPE 1 DIABETES MELLITUS WITH MILD NONPROLIFERATIVE DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA E10.33 TYPE 1 DIABETES MELLITUS WITH MODERATE NONPROLIFERATIVE DIABETIC RETINOPATHY E TYPE 1 DIABETES MELLITUS WITH MODERATE NONPROLIFERATIVE DIABETIC RETINOPATHY WITH MACULAR EDEMA E TYPE 1 DIABETES MELLITUS WITH MODERATE NONPROLIFERATIVE DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA E10.34 TYPE 1 DIABETES MELLITUS WITH SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY E TYPE 1 DIABETES MELLITUS WITH SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY WITH MACULAR EDEMA E TYPE 1 DIABETES MELLITUS WITH SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA E10.35 TYPE 1 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY E TYPE 1 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY WITH MACULAR EDEMA E TYPE 1 DIABETES MELLITUS WITH PROLIFERATIVE DIABETIC RETINOPATHY WITHOUT MACULAR EDEMA E10.36 TYPE 1 DIABETES MELLITUS WITH DIABETIC CATARACT E10.39 TYPE 1 DIABETES MELLITUS WITH OTHER DIABETIC OPHTHALMIC COMPLICATION 03/26/2015 Copyright Health Information Designs, LLC 6
7 ICD-10 Code Description Step 2 (diagnosis of type I diabetes) Required quantity: 1 Look back timeframe: 730 days E10.4 TYPE 1 DIABETES MELLITUS WITH NEUROLOGICAL COMPLICATION E10.40 TYPE 1 DIABETES MELLITUS WITH DIABETIC NEUROPATHY, UNSPECIFIED E10.41 TYPE 1 DIABETES MELLITUS WITH DIABETIC MONONEUROPATHY E10.42 TYPE 1 DIABETES MELLITUS WITH DIABETIC POLYNEUROPATHY E10.43 TYPE 1 DIABETES MELLITUS WITH DIABETIC AUTONOMIC (POLY)NEUROPATHY E10.44 TYPE 1 DIABETES MELLITUS WITH DIABETIC AMYOTROPHY E10.49 TYPE 1 DIABETES MELLITUS WITH OTHER DIABETIC NEUROLOGICAL COMPLICATION E10.5 TYPE 1 DIABETES MELLITUS WITH CIRCULATORY COMPLICATIONS E10.51 TYPE 1 DIABETES MELLITUS WITH DIABETIC PERIPHERAL ANGIOPATHY WITHOUT GANGRENE E10.52 TYPE 1 DIABETES MELLITUS WITH DIABETIC PERIPHERAL ANGIOPATHY WITH GANGRENE E10.59 TYPE 1 DIABETES MELLITUS WITH OTHER CIRCULATORY COMPLICATIONS E10.6 TYPE 1 DIABETES MELLITUS WITH OTHER SPECIFIED COMPLICATIONS E10.61 TYPE 1 DIABETES MELLITUS WITH DIABETIC ARHROPATHY E TYPE 1 DIABETES MELLITUS WITH DIABETIC NEUROPATHIC ARTHROPATHY E TYPE 1 DIABETES MELLITUS WITH OTHER DIABETIC ARTHROPATHY E10.62 TYPE 1 DIABETES MELLITUS WITH SKIN COMPLICATION E TYPE 1 DIABETES MELLITUS WITH DIABETIC DERMATITIS E TYPE 1 DIABETES MELLITUS WITH FOOT ULCER E TYPE 1 DIABETES MELLITUS WITH OTHER SKIN ULCER E TYPE 1 DIABETES MELLITUS WITH OTHER SKIN COMPLICATIONS E10.63 TYPE 1 DIABETES MELLITUS WITH ORAL COMPLICATIONS E TYPE 1 DIABETES MELLITUS WITH PERIODONTAL DISEASE E TYPE 1 DIABETES MELLITUS WITH OTHER ORAL COMPLICATIONS E10.64 TYPE 1 DIABETES MELLITUS WITH HYPOGLYCEMIA E TYPE 1 DIABETES MELLITUS WITH HYPOGLYCEMIA WITH COMA E TYPE 1 DIABETES MELLITUS WITH HYPOGLYCEMIA WITHOUT COMA E10.65 TYPE 1 DIABETES MELLITUS WITH HYPERGLYCEMIA E10.69 TYPE 1 DIABETES MELLITUS WITH OTHER SPECIFIED COMPLICATION E10.8 TYPE 1 DIABETES MELLITUS WITH UNSPECIFIED COMPLICATIONS E10.9 TYPE 1 DIABETES MELLITUS WITHOUT COMPLICATIONS 03/26/2015 Copyright Health Information Designs, LLC 7
8 Step 3 (alternate therapy) Required quantity: 1 Look back timeframe: 180 days Label Name GCN HUM INSULIN NPH/REG INSULIN HM HUM INSULIN NPH/REG INSULIN HM HUM INSULIN NPH/REG INSULIN HM HUM INSULIN NPH/REG INSULIN HUM INSULIN ASP PRT/IINSULIN ASPART INSULIN ASP PRT/INSULIN ASPART INSULIN ASP PRT/INSULIN ASPART INSULIN ASPART INSULIN ASPART INSULIN ASPART INSULIN DETEMIR INSULIN DETEMIR INSULIN LISPRO INSULIN NPL/INSULIN LISPRO INSULIN NPL/INSULIN LISPRO INSULIN REGULAR, HUMAN INSULIN REGULAR, HUMAN INSULIN REGULAR, HUMAN INSULIN REGULAR, HUMAN INSULIN REGULAR, HUMAN INSULIN ZINC HUMAN REG NPH, HUMAN INSULIN ISOPHANE NPH, HUMAN INSULIN ISOPHANE NPH, HUMAN INSULIN ISOPHANE /26/2015 Copyright Health Information Designs, LLC 8
9 PDL Edit Criteria References 1. Clinical Pharmacology [online database]. Tampa, FL: Elsevier / Gold Standard, Inc.; Available at Accessed on April 17, ICD-9-CM Diagnosis Codes, Volume Available at Accessed on April 17, ICD-10-CM Diagnosis Codes, Volume Available at Accessed on April 17, Lantus prescribing information. Bridgewater, NJ: Sanofi-Aventis U.S. LLC. December /26/2015 Copyright Health Information Designs, LLC 9
10 Publication History The Publication History records the publication iterations and revisions to this document. Notes for the most current revision are also provided in the Revision Notes on the first page of this document. Publication Date Notes 05/01/2014 Initial publication and posting on website. 01/22/2015 Lantus moved from non-preferred status to preferred status. Edit removed. 03/26/2015 Lantus no longer requires a PDL edit. Guide removed from website. 03/26/2015 Copyright Health Information Designs, LLC 10
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Criteria Information Included in this Document DPP-4 Inhibitor Criteria A: Alogliptin 6.25mg, Januvia 25mg, Nesina 6.25mg, Onglyza
Sitagliptin (Januvia)
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document 25mg Drugs requiring prior authorization: the list of drugs requiring prior
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Combination Agents
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Combination Agents This criteria was recommended for review by an MCO to ensure appropriate
Texas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Thiazolidinediones Clinical Edit Information Included in this Document Thiazolidinediones Drugs requiring prior authorization: the
Lidoderm (Lidocaine) Patch
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
Byetta (Exenatide Injection)
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Anthem Blue Cross Life and Health Insurance Company are
page 1 Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Anthem Blue Cross Life and Health Insurance Company are independent licensees of the Blue Cross Association.
Continuous Glucose Monitoring System
Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2016 Section: DME Place(s)
Victoza (Liraglutide) Solution for Injection
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
Glycated Hemoglobin/Glycated Protein
190.21 - Glycated Hemoglobin/Glycated Protein The management of diabetes mellitus requires regular determinations of blood glucose levels. Glycated hemoglobin/protein levels are used to assess long-term
Continuous Glucose Monitoring System
Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2017 Section: DME Place(s)
Medical Policy An independent licensee of the Blue Cross Blue Shield Association.
Insulin Pump Page 1 of 12 Medical Policy An independent licensee of the Blue Cross Blue Shield Association. Title: Insulin Pump Professional Original Effective Date: January 1, 1999 Revision Date(s): June
Texas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
Continuous Glucose Monitoring System
Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 4/1/2018 Section: DME Place(s)
Amitiza (Lubiprostone)
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
Texas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
Glucagon-Like Peptide (GLP-1) Receptor Agonists Clinical Edit Criteria
Glucagon-Like Peptide (GLP-1) Receptor Agonists Clinical Edit Criteria Drug/Drug Class: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Superior HealthPlan follows the guidance of the Texas Vendor Drug
Therapeutic Shoes for Diabetics
Last Review Date: August 11, 2017 Number: MG.MM.DM.03bC8v2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
Coding spotlight: diabetes provider guide to coding the diagnosis and treatment of diabetes
Medicaid Managed Care December 2018 provider guide to coding the diagnosis and treatment of diabetes Diabetes mellitus is a chronic disorder caused by either an absolute decrease in the amount of insulin
Methylnaltrexone Bromide (Relistor)
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
Texas Prior Authorization Program Clinical Criteria
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Criteria Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
Provider Bulletin December 2018 Coding spotlight: diabetes provider guide to coding the diagnosis and treatment of diabetes
Medi-Cal Managed Care L. A. Care Provider Bulletin December 2018 provider guide to coding the diagnosis and treatment of diabetes Diabetes mellitus is a chronic disorder caused by either an absolute decrease
revolutionehr.com 2019 Clinical Quality Measure Scoring Guide
revolutionehr.com 2019 Clinical Quality Measure Scoring Guide Clinical quality measures, or CQMs, are statistics that seek to quantify the quality of services performed by health care providers. These
Sample. V18.2 Special Report: Postpartum Readmissions What Drives Your Rate?
V18.2 Special Report: Postpartum Readmissions What Drives Your Rate? INTRODUCTION In FY 2013, the Center for Medicare and Medicaid Services (CMS) began the Hospital Readmission Reduction Program (HRRP)
Asthma J45.20 Mild, uncomplicated J45.21 Mild, with (acute) exacerbation J45.22 Mild, with status asthmaticus
A Fib & Flutter I48.0 Paroxysmal atrial fibrillation I48.1 Persistent atrial fibrillation I48.2 Chronic atrial fibrillation I48.3 Typical atrial flutter Asthma J45.20 Mild, uncomplicated J45.21 Mild, with
Contractor Information. LCD Information. Local Coverage Determination (LCD): HOMOCYSTeine Level, Serum (L34419) Document Information
Local Coverage Determination (LCD): HOMOCYSTeine Level, Serum (L34419) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor
Texas Prior Authorization Program Clinical Edit Criteria. H.P. Acthar
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
COMPREHENSIVE DIABETES CARE
COMPREHENSIVE DIABETES CARE APPLICATIONS OBJECTIVE Purpose of Measure: ELIGIBLE POPULATION Which members are included? STANDARD OF CARE What screening should be done? HbA1c Eye Exam Blood Pressure Nephropathy
Medical Policy Original Effective Date: April 1999 Revised Date: 07/25/2018 Page 1 of 36
Page 1 of 36 Content This includes the following items: 1. Home Blood Glucose Monitors: Prior Authorization is not required. 2. Insulin pumps, cartridges and reservoirs. Prior Authorization is not required.
Texas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document - Oral Drugs requiring prior authorization: the list of drugs requiring prior
Fee for Service Pay for Performance Program Guidelines Program Year
Fee for Service Pay for Performance Program Guidelines 2018 Program Year 2 General Program Guidelines Table of Contents General Program Guidelines... 4 Program Overview... 4 Provider Participation Eligibility...
Injectable Agents for the Treatment of Pulmonary Arterial Hypertension (PAH)
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Injectable Agents for the Treatment of Pulmonary Arterial Hypertension (PAH) Clinical Edit Information Included in this Document
2017 Clinical Quality Measures
2017 Clinical Quality Measures Clinical quality measures, or CQMs, are statistics that seek to quantify the quality of services performed by health care providers. These statistics involve data related
Medical Policy Routine Foot Care and Debridement of Toenails
Medical Policy Routine Foot Care and Debridement of Toenails Table of Contents Policy: Commercial Coding Information Information Pertaining to All Policies Policy: Medicare Description Endnotes Authorization
Agents for the Treatment of Hepatitis C
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
Diclofenac 3% Gel, Diclofenac 1.5% and 2% Topical Solution
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class, Diclofenac 1.5% and 2% Topical Solution This criteria was recommended for review by an MCO to ensure appropriate and safe utilization
Drug Effectiveness Review Project Summary Report Long acting Insulins
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
Prior Authorization Neurontin (gabapentin) 2016
Drugs Requiring Prior Authorization Label Name GCN GABAPENTIN 100 MG CAPSULE 00780 GABAPENTIN 300 MG CAPSULE 00781 GABAPENTIN 400 MG CAPSULE 00782 GABAPENTIN 250 MG/5 ML SOLN 13235 GABAPENTIN 600 MG TABLET
Expanded Fall Risk Factors, Locations of Data Extraction, and Coding. Diastolic blood pressure value (mmhg) Calculated body mass index
Appendix B Expanded Fall Risk Factors, Locations of Data Extraction, and Coding Factor Location Coding Blood pressure systolic Blood pressure diastolic Body mass index Systolic blood pressure value (mmhg)
Texas Prior Authorization Program Clinical Criteria
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Aldurazyme Adagen Carbaglu Ceprotin Elaprase Fabrazyme Lumizyme Naglazyme Orfandin Ravicti Vimizim Note: Click the hyperlink to navigate
Medical Policy Original Effective Date: Revised Date: Page 1 of 23
Page 1 of 23 Disclaimer Description Coverage Determination Refer to the member s specific benefit plan and Schedule of Benefits to determine coverage. This may not be a benefit on all plans or the plan
Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Retirement Date N/A
Local Coverage Determination (LCD): Laparoscopic Sleeve Gastrectomy for Severe Obesity (L34238) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Artificial Pancreas Device Systems Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Artificial Pancreas Device Systems Professional Institutional Original
Texas Prior Authorization Program Clinical Criteria
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Information Included in this Document Xifaxan 200mg Drugs requiring prior authorization: the list of drugs requiring prior authorization
Accepted. Original Article. I-Ting Liu 1, Ru-Yi Huang 1,2, Cheuk-Kwan Sun 3,4,Chi-Wei Lin 1,2
E-Da Medical Journal 2017;4(4):10-18 Original Article The Prognosis and Healthcare Expenditure of Newly Diagnosed Diabetic Patients Are There Differences Between Family Physicians and the Internists? I-Ting
Texas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Xifaxan 200mg Drugs requiring prior authorization: the list of drugs requiring
Texas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Provigil (Modafinil) Drugs requiring prior authorization: the list of drugs
Texas Prior Authorization Program Clinical Criteria. This criteria was recommended for review by an MCO to ensure appropriate and safe utilization.
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class This criteria was recommended for review by an MCO to ensure appropriate and safe utilization. Clinical Information Included in this
Diabetes Mellitus. and coding the complications that can occur
Diabetes Mellitus and coding the complications that can occur As a coder.don t get stuck in neutral You have to keep moving forward with the new compliances and codes Diabetes Mellitus with. let s take
Diabetic Complications: Diagnosis, Documentation, Coding, and Compliance
Diabetic Complications: Diagnosis, Documentation, Coding, and Compliance Richard D. Pinson, MD, FACP, CCS Principal and Medical Director Pinson and Tang, LLC CDI Educators and Consultants Houston, TX 1
Texas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Aldara 5% Cream Drugs requiring prior authorization: the list of drugs requiring
New Drug Evaluation: Insulin degludec/aspart, subcutaneous injection
New Drug Evaluation: Insulin degludec/aspart, subcutaneous injection Date of Review: March 2016 End Date of Literature Search: November 11, 2015 Generic Name: Insulin degludec and insulin aspart Brand
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Artificial Pancreas Device Systems Page 1 of 16 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Artificial Pancreas Device Systems Professional Institutional Original
DIABETES CODING AND DOCUMENTATION COMPLIANCE
BC ADVANTAGE AUDIO SERIES: DIABETES CODING AND DOCUMENTATION COMPLIANCE 1 Presented by: Darlene Boschert, RHIA, CPC, CPC-H, CPC-I Providing LOW-COST educational resources for Medical office Professionals
2 Master the ICD 10 Payment System to Prevent Revenue Losses
Master the ICD 10 Payment System to Prevent Revenue Losses Tricia A. Twombly BSN RN HCS D HCS O COS C CHCE AHIMA Approved ICD 10 CM Trainer Senior Director, DecisionHealth Chief Executive Officer, BMSC
Learning Objectives. Novant Health. Novant Health Ambulatory CDI: How We ve Grown!
1 Novant Health Ambulatory CDI: How We ve Grown! Yvonne Whitley, RN, BSN, CPC, CRC, CDEO Supervisor, Novant Health Medical Group Clinical Documentation Improvement Novant Health Winston Salem, NC Learning
Contractor Information. LCD Information. FUTURE Local Coverage Determination (LCD): Routine Foot Care (L35138) Document Information
FUTURE Local Coverage Determination (LCD): Routine Foot Care (L35138) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Please note: Future Effective
Insulin Prior Authorization with optional Quantity Limit Program Summary
Insulin Prior Authorization with optional Quantity Limit Program Summary 1-13,16-19, 20 FDA LABELED INDICATIONS Rapid-Acting Insulins Humalog (insulin lispro) NovoLog (insulin aspart) Apidra (insulin glulisine)
3/20/2017. CONNECTING THE LATEST GUIDANCE FY2017 FOR ICD-10 MATTERS Kyla D. Harrison, RN, BSN, HCS-D, COS-C Visiting Nurse Association of Kansas City
CONNECTING THE LATEST GUIDANCE FY2017 FOR ICD-10 MATTERS Kyla D. Harrison, RN, BSN, HCS-D, COS-C Visiting Nurse Association of Kansas City Coding needs met in many different ways: 1. Fulltime Coders HCS-D
Agenda. American Diabetes Association Diabetic Complications Diabetes Coding Guidelines & ICD-10 Codes Documentation
Diabetes Agenda American Diabetes Association Diabetic Complications Diabetes Coding Guidelines & ICD-10 Codes Documentation American Diabetes Association American Diabetes Association Diabetic Eye Complications
POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): 3/1/2012 Most Recent Review Date (Revised): 4/11/2018 Effective Date: 8/1/2018 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER
ICD-10-CM: The Sage Continues
ICD-10-CM: The Sage Continues UHIMA Kathy DeVault, MSL, RHIA, CCS, CCS-P, FAHIMA UASI Kathy.devault@uasisolutions.com Objectives Review quality documentation Discuss use of unspecified codes Discuss opportunities
Continuous Glucose Monitoring (CGM)
Continuous Glucose Monitoring (CGM) Date of Origin: 02/2001 Last Review Date: 08/22/2018 Effective Date: 08/22/2018 Dates Reviewed: 04/2004, 04/2005, 03/2006, 11/2006, 12/2007, 03/2008, 09/2008, 04/2009,
Chapter. CPT only copyright 2008 American Medical Association. All rights reserved. 15Diabetic Equipment and Supplies
Chapter 15Diabetic Equipment and Supplies 15 15.1 Enrollment...................................................... 15-2 15.2 Benefits, Limitations, and Authorization Requirements......................
CLINICAL MEDICAL POLICY
Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Long Term Use Continuous Glucose Monitoring of Interstitial Fluid MP-040-MD-DE Medical Management Provider Notice Date: 04/15/2018;
Thyroid Testing
190.22 - Thyroid Testing Thyroid function studies are used to delineate the presence or absence of hormonal abnormalities of the thyroid and pituitary glands. These abnormalities may be either primary
Optum360 Learning: Detailed Instruction for Appropriate ICD-10-CM Coding
Optum360 Learning: Detailed Instruction for Appropriate Coding An educational guide to the structure, conventions, and guidelines of coding 2017 Contents Section 1: Introduction...1 Documentation...7 Documentation
Texas Prior Authorization Program Clinical Criteria. Allergen Extracts
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Information Included in this Document Oralair (Mixed Grass Pollens Allergen Extract)) Drugs requiring prior authorization: the
Basal Insulin Drug Class Prior Authorization Protocol
Basal Insulin Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical
Flexeril/Amrix (Cyclobenzaprine)
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
We know these take time to gather, so please plan ahead!
CDL AND INSULIN CHECKLIST Are you a CDL holder who uses insulin for diabetes? As of November 2018, you can get certified to drive faster, with no waiver application process! Please bring all of the following:
ICD-10. An Introduction
ICD-10 An Introduction ICD-10 Worldwide Other countries have been using ICD-10 for many years. Coding professionals there were better prepared with: Human Anatomy and Physiology Understanding of disease
Clinical Policy Title: Artificial pancreas device system
Clinical Policy Title: Artificial pancreas device system Clinical Policy Number: 08.02.07 Effective Date: April 1, 2016 Initial Review Date: November 18, 2015 Most Recent Review Date: February 6, 2018
Diabetic Equipment and Supplies
Diabetic Equipment and Supplies Chapter.1 Enrollment..................................................................... -2.2 Benefits, Limitations, and Authorization Requirements...........................
Supplementary Appendix Contents Table A1 Read Code List for Diabetes Mellitus 2
Supplementary Appendix Contents Table A1 Read Code List for Diabetes Mellitus 2 Table A2 Drugcode list for Diabetes Mellitus 16 Table A3 Ahdcodes list for Diabetes Mellitus 33 Table A4 List of diabetes
Professional CGM Reimbursement Guide
Professional CGM Reimbursement Guide 2015 TABLE OF CONTENTS Coding, Coverage and Payment...2 Coding and Billing...2 CPT Code 95250...3 CPT Code 95251...3 Incident to Billing for Physicians..............................................
To be considered medically necessary, an eligible provider must prescribe all orthotics.
Original Issue Date (Created): 2/1/2018 Most Recent Review Date (Revised): 9/26/2017 Effective Date: 4/1/2018 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER
Agents for Cystic Fibrosis
Texas Prior Authorization Program Clinical Edit Criteria Clinical Edit Information Included in this Document Kalydeco (Ivacaftor) Drugs requiring prior authorization: the list of drugs requiring prior
Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
Frequently Used Tests & ICD-10 Codes
Frequently Used Tests & ICD-10 Codes revised 9/18/2015 Medicare limited coverage policies outline indications for which testing is considered reasonable and necessary. Monitoring of treatment or therapy
CLINICAL MEDICAL POLICY
Policy Name: Policy Number: Approved By: CLINICAL MEDICAL POLICY Long Term Use Continuous Glucose Monitoring of Interstitial Fluid MP-040-MD-WV Medical Management Provider Notice Date: 07/03/2017 Original
FY 2011 WISEWOMAN Approved ICD-9 Code List
243 Congenital hypothyroidism 245.0 Thyroiditis; Acute thyroiditis 245.1 Thyroiditis; Subacute thyroiditis 245.2 Thyroiditis; Chronic lymphocytic thyroiditis 245.3 Thyroiditis; Chronic fibrous thyroiditis
CLINICAL MEDICAL POLICY
Policy Name: Policy Number: Approved By: CLINICAL MEDICAL POLICY Long-Term Use Continuous Glucose Monitoring of Interstitial Fluid MP-040-MD-PA Medical Management Provider Notice Date: 04/01/2017 Original
Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Jurisdiction Oregon. Retirement Date N/A
Local Coverage Determination (LCD): Urinalysis Policy (L34060) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information Contractor Name
ADMELOG, NOVOLIN, NOVOLOG, and FIASP
ADMELOG, NOVOLIN, NOVOLOG, and FIASP Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
ClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
Professional CGM Reimbursement Guide
Professional CGM Reimbursement Guide 2017 TABLE OF CONTENTS Coding, Coverage and Payment...2 Coding and Billing...2 CPT Code 95250...3 CPT Code 95251...3 Incident to Billing for Physicians..............................................
Fentanyl Agents Clinical Edit Criteria
Fentanyl Agents Clinical Edit Criteria Drug/Drug Class: Fentanyl Agents Superior HealthPlan follows the guidance of the Texas Vendor Drug Program (VDP) for all clinical edit criteria. Superior has adjusted
GLUCOSE TESTING-BLOOD
648.83 ABNORMAL GLUCOSE TOLERANCE COMPLICATING PREGNANCY, CHILDBIRTH OR THE PUERPERIUM, ANTEPARTUM CONDITION OR 648.84 ABNORMAL GLUCOSE TOLERANCE COMPLICATING PREGNANCY, CHILDBIRTH OR THE PUERPERIUM, POSTPARTUM
Revenue Cycle Solutions Consulting & Management Services Why Words Matter Through an Endocrinology Lens 2015 The Advisory Board Company advisory.
Revenue Cycle Solutions Consulting & Management Services Why Words Matter Through an Endocrinology Lens Key Objectives for Today s Session 1. Develop understanding of the role documentation plays in determining
CONTINUOUS GLUCOSE MONITORING AND INSULIN DELIVERY FOR MANAGING DIABETES
UnitedHealthcare Community Plan Medical Policy CONTINUOUS GLUCOSE MONITORING AND INSULIN DELIVERY FOR MANAGING DIABETES Policy Number: CS024.M Effective Date: October 1, 2018 Table of Contents Page INSTRUCTIONS
Drug Use Criteria: Exogenous Insulin Products
Texas Vendor Program Use Criteria: Exogenous Products Publication History 1. Developed June 2017. Notes: Information on indications for use or diagnosis is assumed to be unavailable. All criteria may be
Cardiometabolic Indicators Documentation
Cardiometabolic Indicators Documentation Updated: October 2009 Created by : PSYCKES Description: 2 The percentage of consumers of all ages who have been diagnosed with cardiometabolic disorders during
Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria
Drug/Drug Class Antipsychotics Clinical Criteria Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria Prior
Risk Adjustment Documentation & Coding Improvement Reference Information for 2017
Risk Adjustment Documentation & Coding Improvement Reference Information for 2017 In today s quality and patient-centered health care environment, the importance of accurate, specific and thorough medical
Insulin Prior Authorization Criteria For Individuals Who Purchased BlueCare/KS Solutions/EPO Products
Insulin Prior Authorization Criteria For Individuals Who Purchased BlueCare/KS Solutions/EPO Products FDA LABELED INDICATIONS 1-13,16-21 Rapid-Acting Indication Onset Peak Duration Insulins Admelog (insulin
Insulin Prior Authorization Criteria For Individuals who Purchased BlueCare / KS Solutions products
Insulin Prior Authorization Criteria For Individuals who Purchased BlueCare / KS Solutions products FDA LABELED INDICATIONS 1-13,16-20 Rapid-Acting Indication Onset Peak Duration Insulins Fiasp (insulin
1/3/2008. Karen Burke Priscilla LeMone Elaine Mohn-Brown. Medical-Surgical Nursing Care, 2e Karen Burke, Priscilla LeMone, and Elaine Mohn-Brown
Medical-Surgical Nursing Care Second Edition Karen Burke Priscilla LeMone Elaine Mohn-Brown Chapter 17 Caring for Clients with Diabetes Mellitus Diabetes Mellitus Chronic disease Not a single disorder